ClinicalTrials.gg
CompletedNCT05036512Updated Jul 25, 2023

A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

A Phase 1 interventional study of GBT021601 in Sickle Cell Disease, sponsored by Pfizer. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-25.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled Dec 2020, registered Aug 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Anemia, Sickle Cell by Pfizer — 1 open to participants now, 1 under way, 1 of them phase 3. Anemia, Sickle Cell · Pfizer.

Enrollment
10th of 27
129 · median 52
Started
2020
with 4 others
Phase 1
10 of 32
none open now
Registered
22nd of 32
by date

Among the 32 studies in Anemia, Sickle Cell by Pfizer, this one is the 10th largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2020, is one of 10 in phase 1, and was the 22nd registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

1 of the 32 studies in Anemia, Sickle Cell by Pfizer is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Anemia, Sickle Cell by Pfizer, or all of them as a file.
02

Study summary

This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.

Read the detailed description

This is a randomized, double-blind, placebo controlled, single and multiple ascending dose study in healthy participants.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females ≥ 18 to ≤ 55 years of age
  • ≥ 18.0 to ≤ 30.0 kg/m2
  • Body weight ≥ 50 kg at screening and Day -1

Exclusion criteria

Exclusion Criteria:

  • Positive pregnancy test or currently breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo as a tablet or capsule with dose based off of preceding cohort's data.

    Drug: GBT021601

  • Experimental
    GBT021601

    GBT021601 as a tablet or capsule with dose based off of preceding cohort's data.

    Drug: GBT021601

Interventions

  • Administered orally with water as a single dose in the morning.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Safety, as assessed by frequency and severity of adverse events (AEs)

    AEs will be coded to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized.

    Time frame: 119 days from screening Part A, 134 days from screening Part B

  2. Safety, as assessed by changes in Heart Rate.

    Number of participants with changes in heart rate (bpm) as compared to baseline.

    Time frame: 119 days from screening Part A, 134 days from screening Part B

  3. Safety, as assessed by changes in eGFR

    Number of participants with changes in eGFR from baseline

    Time frame: 119 days from screening Part A, 134 days from screening Part B

  4. Safety, as assessed by changes in alanine aminotransferase (ALT)

    Number of participants with changes in alanine aminotransferase (ALT)

    Time frame: 119 days from screening Part A, 134 days from screening Part B

  5. Safety, as assessed by changes in Blood pressure

    Number of participants with changes in systolic (mmHg) and diastolic (mmHg) blood

    Time frame: 119 days from screening Part A, 134 days from screening Part B

  6. Plasma concentration

    Time of Cmax

    Time frame: 119 days from screening Part A

  7. Plasma concentration

    Cmax on D1-D15

    Time frame: 134 days from screening Part B

Secondary outcomes

  1. Determine whole blood concentration of GBT021601

    Hemoximetry will be used to assess oxygen saturation in whole blood by generating oxygen equilibrium curves (OECs) which relate the extent of Hb-O2 saturation to the partial pressure of O2 (pO2) and measure the binding affinity of O2 to Hb.

    Time frame: 119 days from screening Part A

  2. Determine plasma concentration of GBT021601.

    With dosing data from each cohort determine the steady-state maximum plasma/whole blood concentration (Cmax).

    Time frame: 134 days from screening Part B

  3. Safety, as assessed by changes in QTcF

    Number of participants with changes in the QTcF interval from baseline

    Time frame: 119 days from screening Part A, 134 days from screening Part B

07

Study locations

4 sites
  • ICON Early Phase Services, LLC
    San Antonio, Texas 78209, United States
  • Harry Perkins Institute of Medical Research
    Nedlands, Western Australia 6009, Australia
  • Linear Clinical Research
    Nedlands, Western Australia 6009, Australia
  • Oxford Compounding
    North Perth, Western Australia 6006, Australia
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Nov 2022, 22 months.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 22 months is close to that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2021
First posted
Sep 5, 2021
StartActual
Dec 9, 2020
Primary completionActual
Nov 2, 2022
CompletionActual
Feb 7, 2023
Last update
Jul 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05036512
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Dec 9, 2020
Primary completion
Nov 2, 2022
Completion
Feb 7, 2023
Last update
Jul 25, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osivelotor

Start the discussion